Volex (AIM: VLX) upgrades FY2026 revenue to at least $1.22bn as AI data centre demand doubles and board eyes Main Market move
Can inhaled nintedanib improve tolerability and adherence in IPF treatment, according to Avalyn Pharma Inc.?
Read More 6 minute read General business news Can industrial carve-outs still create alpha in a higher-rate, lower-multiple environment? Can carve-outs still deliver alpha in a high-rate, low-multiple world? We explore why PE firms like Carlyle are doubling down on industrial spinouts. byVenkateshOctober 13, 2025